A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib.

Trial Profile

A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2015

At a glance

  • Drugs Cetuximab; Erlotinib
  • Indications Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top